Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
RESEARCH TOOLSreports
IOVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.57 - $18.33
Previous CloseN/A
Volume2.95M
Average Volume (3M)8.26M
Market Cap
$1.90B
Enterprise Value$2.53B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Feb 26, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding304,780,800
10 Day Avg. Volume10,982,279
30 Day Avg. Volume8,259,683
Standard Deviation0.27
R-Squared0.01
Alpha0.00250
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.97
Price to Cash Flow (P/CF)-8.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-264.39
Enterprise Value/Ebitda-6.38
Forecast
1Y Price Target
$21.79Price Target Upside257.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Iovance Biotherapeutics News
PremiumCompany Announcements
Iovance Biotherapeutics Optimizes Headquarters for Cost Efficiency
PremiumCompany Announcements
Iovance Biotherapeutics’ Strong Q3 2024 Performance
---
Bulls Say, Bears Say
Bulls Say
Cash PositionIovance ended 3Q24 with $403.8MM in cash and cash equivalents, providing a strong financial position.
Financial Performance3Q24 financial results were higher than consensus revenue estimates, indicating strong financial performance.
Revenue GrowthSales continue to ramp with 39 patients dosed in the first month+ of Q4 demonstrating that Amtagvi is continuing strong growth.
Bears Say
Clinical TrialsIOVA highlighted that the rate is getting closer to its clinical trial experience, with improvements noted in reducing scrap cost.
Insurance ChallengesIOVA noted there has been no ultimate denial on insurance.
Operational EfficiencyIovance's centers have begun to streamline operations, which could improve operational efficiency and patient throughput.
---
Ownership Overview
9.63% Insiders
17.21% Mutual Funds
0.71% Other Institutional Investors
55.72% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $5.57 and its highest was $18.33 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $1.90B.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is Feb 26, 2025 which is in 19 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Nov 07, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.299 by $0.019.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.27.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 304,780,800 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.299. Following the earnings report the stock price went down -13.844%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in IOVA
---
Iovance Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.79 (257.21% Upside)
$21.79 (257.21% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 97%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $503.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.30%
12-Months-Change
Fundamentals
Return on Equity
-53.01%
Trailing 12-Months
Asset Growth
16.29%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
---
IOVA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant revenue growth, successful commercial adoption of Amtagvi, and positive clinical trial results. Despite net losses and initial challenges in ATC performance, the overall sentiment is positive due to surpassing revenue expectations and a solid financial outlook.Read More>---
IOVA Stock 12 Month Forecast
Average Price Target
$21.79
▲(257.21% Upside)
Technical Analysis
Best Analysts Covering IOVA
1 Year
1 Year Success Rate
15/32 ratings generated profit
1 Year Average Return
+17.84%
reiterated a buy rating 12 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +17.84% per trade.
---